Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences Press Release / May 1, 2024June 3, 2024
Stealth BioTherapeutics to Present at the Baird 2023 Biotech Discovery Series Press Release / December 4, 2023June 3, 2024
Stealth BioTherapeutics to Present at the 2023 Ophthalmology Innovation Source Summit Press Release / November 28, 2023June 3, 2024
Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration Press Release / June 12, 2023June 3, 2024
Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022 Press Release / May 23, 2022June 3, 2024
Stealth Biotherapeutics Announces Data from ReCLAIM-2 Phase 2 Trial of Elamipretide in Geographic Atrophy Press Release / May 2, 2022June 3, 2024
Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022) Press Release / March 24, 2022June 3, 2024
Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration Press Release / March 17, 2022June 3, 2024
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit Press Release / February 22, 2022June 3, 2024
Last Patient Completes Treatment in Stealth BioTherapeutics’ Phase 2 Geographic Atrophy Clinical Trial Press Release / February 15, 2022June 3, 2024
